Myasthenia gravis (MG) affects roughly 12.4 out of every 100,000 people worldwide, making it a rare autoimmune disease. In the United States, an estimated 82,715 adults were living with MG in 2021, which works out to about 32 cases per 100,000 people. The condition qualifies for orphan drug designation from the FDA, a classification reserved for diseases affecting fewer than 200,000 Americans at any given time.
How MG Compares to Other Rare Diseases
To put MG’s rarity in perspective, you’d need to gather roughly 8,000 people in a room before you’d statistically expect to find one person with the condition (using global figures). It’s more common than ALS, which affects about 5 per 100,000, but far less common than multiple sclerosis, which affects around 150 per 100,000 in the US. MG sits in a middle tier of rare neurological conditions: uncommon enough that many primary care doctors see only a handful of cases in their careers, but prevalent enough that most neurologists are familiar with it.
Who Gets MG
MG follows a distinctive pattern by age and sex. Women are more likely to develop it before age 40, while men are more commonly diagnosed after age 50. This creates a bimodal peak, meaning cases cluster around two separate age ranges rather than rising steadily with age. The condition can appear at any point in life, including childhood, though juvenile MG is considered very rare and lacks solid prevalence data because so few children are affected.
Race also shapes how the disease presents. In a study of MG patients in Alabama, African American patients developed symptoms an average of 18 years earlier than white patients and were twice as likely to be female. African American patients also tended to have more severe disease at onset and were more likely to test positive for a less common antibody subtype. That said, the overall occurrence of MG does not appear to be dramatically higher in any single racial group.
Subtypes Vary in Rarity
Not all forms of MG are equally common. About 75% of patients test positive for antibodies that attack acetylcholine receptors, the docking sites where nerves communicate with muscles. This is the most typical form. A much smaller group, roughly 1.5 to 2% of patients, carries a different antibody that targets a protein involved in maintaining the connection between nerve and muscle. The remaining patients test negative for both known antibodies. Within that group, only about 19% carry a third, even rarer antibody type. These subtypes matter because they can influence symptoms, severity, and which treatments work best.
MG also divides into ocular and generalized forms. Some people only experience weakness in the muscles controlling their eyelids and eye movement. About 30 to 40% of patients stay in this ocular category permanently. The remaining 50 to 70% progress to generalized MG, where weakness spreads to the limbs, throat, or breathing muscles. This progression typically happens within the first two years of symptoms appearing.
Why It Often Takes So Long to Diagnose
Part of what makes MG feel even rarer than it is: the average time from first symptoms to a confirmed diagnosis is about 331 days, nearly a full year. Some patients receive a diagnosis within a week, while others wait over 12 years. The symptoms themselves contribute to the delay. Drooping eyelids, double vision, and fatigue that comes and goes can mimic dozens of other conditions. Because MG is uncommon, it may not be the first thing a doctor considers, especially in younger patients or those whose symptoms are subtle.
Modern Outcomes Have Transformed the Picture
MG used to be far more dangerous than it is today. Myasthenic crisis, a life-threatening episode where breathing muscles weaken severely, once killed more than 50% of patients who experienced it. Modern intensive care and immune-targeted treatments have brought that hospital mortality rate down to between 2 and 22%, depending on the setting and severity.
Overall mortality from MG is now very low. China’s national data from 2020 showed an age-adjusted death rate of 1.86 per million people, with men dying at roughly twice the rate of women. Studies from Europe and the United States suggest that with current treatments, many MG patients can expect a normal or near-normal lifespan. The disease is chronic and requires ongoing management, but the prognosis has improved dramatically over the past several decades.
Rising Prevalence Despite Rarity
Interestingly, MG appears to be getting more common in the data, though not necessarily because more people are developing it. Better diagnostic tools, wider awareness among clinicians, and aging populations (who are more susceptible to late-onset MG) all contribute to rising case counts. China’s national data showed MG-related mortality increasing by an average of 3.5% per year between 2013 and 2020, which likely reflects improved detection alongside genuine demographic shifts. As populations age globally, the number of people living with MG is expected to keep climbing even though the disease remains rare by any standard definition.